LLY
Eli Lilly and Company
LLY has the edge over VCYT overall, supported by stronger modeled upside and lower modeled downside.
VCYT
Veracyte, Inc.
VCYT offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
VCYT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
VCYT's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
VCYT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 16x | $24.63 | — |
| Forward | 16x | $24.63 | — |
| Cheap | 35x | $54.07 | +120% |
| Fair | 64x | $99.04 | +302% |
| Expensive | 105x | $162 | +558% |
Historical ranges are pointers, not guarantees.
VCYT has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over VCYT on the outlook, with more favorable valuation and earnings expectations.
VCYT Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect VCYT's revenue to grow, but its profitability to weaken.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
VCYT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | -1.2% |
| Q3 2026 | $1.54 | +295% |
| Q2 2026 | $1.40 | +312% |
| Q1 2026 | $1.08 | +157% |
| Q4 2025 | $0.82 | +165% |
| Q3 2025 | $0.39 | +$0.53 |
| Q2 2025 | $0.34 | +$1.08 |
| Q1 2025 | $0.42 | +$1.35 |
| Q4 2024 | $0.31 | +$1.33 |
VCYT's earnings per share have climbed steadily: $1.54 over the past year, about four times what it earned the year before, and higher year over year for nine quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over VCYT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over VCYT on profitability, with a higher operating margin.
VCYT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $151.8M | +15% |
| Q2 2026 | $150.3M | +15% |
| Q1 2026 | $139.1M | +21% |
| Q4 2025 | $140.6M | +19% |
| Q3 2025 | $131.9M | +14% |
| Q2 2025 | $130.2M | +14% |
| Q1 2025 | $114.5M | +18% |
| Q4 2024 | $118.6M | +21% |
VCYT's revenue has grown year over year every quarter since late 2020: $152M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -6.5 points |
| Q2 2026 | 15% | +19 points |
| Q1 2026 | 16% | +14 points |
| Q4 2025 | 26% | +23 points |
| Q3 2025 | 17% | +7 points |
| Q2 2025 | -4% | -8.1 points |
| Q1 2025 | 2.5% | +7.3 points |
| Q4 2024 | 3.5% | +40 points |
VCYT's operating margin was 11% last quarter, down 6.5 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
VCYT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $37.9M | -9.6% |
| Q2 2026 | $43M | +33% |
| Q1 2026 | $32.3M | +810% |
| Q4 2025 | $48.8M | +139% |
| Q3 2025 | $42M | +51% |
| Q2 2025 | $32.3M | +21% |
| Q1 2025 | $3.5M | +$14.6M |
| Q4 2024 | $20.4M | +56% |
VCYT has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over VCYT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
VCYT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +724K shares |
| 1 year | +3.9% | +3.1M shares |
| 3 years | +14% | +10M shares |
| 5 years | +19% | +13M shares |
| Available history | +69% | +33.7M shares |
VCYT has 83M diluted shares, up 3.9% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
VCYT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -2.4x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -4.6x | Net Cash |
| Q3 2025 | -6.7x | Net Cash |
| Q2 2025 | -6.0x | Net Cash |
| Q1 2025 | -4.0x | Net Cash |
| Q4 2024 | -6.0x | Net Cash |
VCYT has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
VCYT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.0 | Neutral |
| Stochastic | 23.4 | Neutral |
VCYT's weekly RSI is 33 (neutral) and its Stochastic is 23 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
VCYT PE vs Healthcare Sector
| Metric | VCYT | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 26x | 38% below |
| PE % | 1 | 29 | 28 pts below |
VCYT has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over VCYT on trend strength, trading above more of its moving averages.
VCYT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $40.8 | 40% below |
| 20 week MA | $45.0 | 45% below |
| 50 week MA | $41.9 | 41% below |
| 100 week MA | $37.8 | 35% below |
| 200 week MA | $31.8 | 23% below |
VCYT is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over VCYT on returns for 2026, with the stronger performance.
VCYT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $55.8 | +92% |
| 2021 | $55.8 | $40.5 | -27% |
| 2022 | $40.5 | $24.6 | -39% |
| 2023 | $24.6 | $27.5 | +12% |
| 2024 | $27.5 | $40.1 | +46% |
| 2025 | $40.1 | $42.5 | +5.9% |
| 2026 YTD | $42.5 | $24.6 | -42% |
VCYT is down 42% so far in 2026, after finishing higher in four of the previous six years.